{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:07:57Z","timestamp":1791180477905,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2001,11,27]]},"DOI":"10.1212\/wnl.57.10.1829","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:54:14Z","timestamp":1336917254000},"page":"1829-1834","source":"Crossref","is-referenced-by-count":207,"title":["Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models"],"prefix":"10.1212","volume":"57","author":[{"given":"Francesco","family":"Bibbiani","sequence":"first","affiliation":[{"name":"From the Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin D.","family":"Oh","sequence":"additional","affiliation":[{"name":"From the Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N.","family":"Chase","sequence":"additional","affiliation":[{"name":"From the Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199712000-00004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200001)47:1<122::AID-ANA21>3.0.CO;2-9"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-1931(00)00018-5"},{"key":"e_1_3_2_5_2","first-page":"II36","volume":"247","year":"2000","unstructured":"Chase TN, Oh JD, Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol . 2000; 247: II36\u2013II42. Review.","journal-title":"J Neurol"},{"key":"e_1_3_2_6_2","first-page":"II36","volume":"247","year":"2000","unstructured":"Chase TN, Oh JD, Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol . 2000; 247: II36\u2013II42. Review.","journal-title":"J Neurol"},{"key":"e_1_3_2_7_2","first-page":"S72","volume":"55","year":"2000","unstructured":"Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson\u2019s disease: implications for the early use of COMT inhibitors. Neurology . 2000; 55: S72\u2013S81. Review.","journal-title":"Neurology"},{"key":"e_1_3_2_8_2","first-page":"13","volume":"3","year":"1975","unstructured":"Hornykiewicz O. Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser . 1975; 3: 13\u201321.","journal-title":"Natl Inst Drug Abuse Res Monogr Ser"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4547(19980601)52:5<591::AID-JNR11>3.0.CO;2-5"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb10192.x"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410080603"},{"key":"e_1_3_2_12_2","first-page":"545","volume":"69","year":"1996","unstructured":"Melamed E, Zoldan J, Friedberg G, Ziv I, Weizmann A. Involvement of serotonin in clinical features of Parkinson\u2019s disease and complications of L-DOPA therapy. Adv Neurol . 1996; 69: 545\u2013550.","journal-title":"Adv Neurol"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0031-6997(25)06671-2","volume":"43","year":"1991","unstructured":"Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev . 1991; 43: 587\u2013604.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(80)90368-9"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(97)00176-0"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050265"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0149-7634(95)00057-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080205"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.8.1589"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130507"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)90796-X"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90783-3"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199402000-00008"},{"key":"e_1_3_2_24_2","first-page":"376","volume":"54","year":"1991","unstructured":"Kleedorfer B, Lees AJ, Stern GM. Buspirone in the treatment of levodopa-induced dyskinesias. J Neurol Neurosurg Psychiatry . 1991; 54: 376\u2013377.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00234-C"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0022-3565(25)09547-3","volume":"273","year":"1995","unstructured":"Gobert A, Lejeune F, Rivet JM, Audinot V, Newman-Tancredi A, Millan MJ. Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats. J Pharmacol Exp Ther . 1995; 273: 1032\u20131046.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0022-3565(25)38872-5","volume":"269","year":"1994","unstructured":"Kreiss DS, Lucki I. Differential regulation of serotonin (5-HT) release in the striatum and hippocampus by 5-HT1A autoreceptors of the dorsal and median raphe nuclei. J Pharmacol Exp Ther . 1994; 269: 1268\u20131279.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2001.00184.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01273152"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00483-X"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.3.658"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4547(19980215)51:4<541::AID-JNR14>3.0.CO;2-6"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(199809)30:1<71::AID-SYN9>3.0.CO;2-H"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9861(19991018)413:2<219::AID-CNE4>3.0.CO;2-F"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00973745"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199310000-00004"},{"key":"e_1_3_2_37_2","first-page":"277","volume":"29","year":"1992","unstructured":"Henderson J, Yiannikas C, Graham JS. Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson\u2019s disease. Clin Exp Neurol . 1992; 29: 277\u2013282.","journal-title":"Clin Exp Neurol"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198610000-00010"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1972.00490160082011"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.11.1383"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.721489.x"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00136-3"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.57.10.1829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T22:56:58Z","timestamp":1743116218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.57.10.1829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11,27]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,11,27]]}},"alternative-id":["10.1212\/WNL.57.10.1829"],"URL":"https:\/\/doi.org\/10.1212\/wnl.57.10.1829","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11,27]]}}}